Company: TXG
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001770787-25-000013
Chunk: 6

Company: 10x Genomics, Inc.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 8
Chunk 6
---
131,661)Purchase of intangible assets(1,000)(923)— Acquisition of business, net of cash acquired— — (4,000)Purchase of marketable securities(48,876)— (282,871)Net cash (used in) provided by investing activities(32,631)133,492 (350,887)Financing activities:Payments on technology license financing arrangement— (5,814)(5,409)Issuance of common stock from exercise of stock options and employee stock purchase plan purchases10,914 19,483 21,226 Net cash provided by financing activities10,914 13,669 15,817 Effect of exchange rate changes on cash, cash equivalents, and restricted cash(164)(33)(44)Net (decrease) increase in cash, cash equivalents, and restricted cash(15,217)131,931 (368,720)Cash, cash equivalents, and restricted cash at beginning of year359,284 227,353 596,073 Cash, cash equivalents, and restricted cash at end of year$344,067 $359,284 $227,353 Supplemental disclosures of cash flow information:Cash paid for interest$— $436 $841 Cash paid for taxes$5,641 $4,927 $3,925 Noncash investing and financing activitiesPurchases of property and equipment included in accounts payable, accrued expenses and other current liabilities$1,351 $3,324 $26,750 Right-of-use assets obtained in exchange for new operating lease liabilities$— $6,518 $16,562 

The accompanying notes are an integral part of these consolidated financial statements.

83